TR
$84.97CAD · 10 mg
- Fat loss & metabolism
The dual-receptor incretin that beat semaglutide outright — 20.2% of body weight lost, against 13.7%.
Read the published research →Ships within 1 business day of payment. Free shipping over $200, tracked across Canada.
- Mol. weight
- 4,813.5
- Sequence
- 39 aa
- Format
- Lyophilized
- Catalog no.
- TR10
View COAs3 reports
| Tested sample | Task number | Analysis date | Measured results | Report |
|---|---|---|---|---|
| 20 mg | 197315 | Jun 30, 2026 | Tirzepatide: 22.53 mg · Purity: 99.647% Labeled 20 mg · Measured 22.53 mg+12.7% | |
| 15 mg | 171261 | Jun 23, 2026 | Tirzepatide: 17.37 mg · Purity: 99.685% Labeled 15 mg · Measured 17.37 mg+15.8% | |
| 30 mg | 171211 | Jun 23, 2026 | Tirzepatide: 35.58 mg · Purity: 99.845% Labeled 30 mg · Measured 35.58 mg+18.6% |
A synthetic peptide that activates both the GIP and GLP-1 receptors, the first such dual agonist to be approved. It is approved for glycaemic control in adults with type 2 diabetes in the US, the EU, Japan and elsewhere.
Full note and sources- Third-party tested · Janoshik · Czech Republic
- Ships from Canada, tracked
For laboratory research use only
What TR does
TR activates two incretin receptors, GIP and GLP-1, where semaglutide activates one, and put directly against it in 751 adults with obesity that difference came out as 20.2% body-weight loss versus 13.7%, with waist circumference down 18.4 cm versus 13.0 cm. Against placebo over 72 weeks in 2,539 adults with obesity and no diabetes, the highest-dose group lost 20.9% of body weight versus 3.1%, and 57% of them lost at least a fifth of their body weight versus 3%. Carried on to 176 weeks in the participants who also had prediabetes, type 2 diabetes was diagnosed in 1.3% on treatment versus 13.3% on placebo. The effects reach past the scale: in adults with moderate-to-severe obstructive sleep apnoea, breathing interruptions fell by 25.3 an hour versus 5.3 on placebo, and in adults with heart failure with preserved ejection fraction and obesity, cardiovascular death or a worsening heart-failure event occurred in 9.9% versus 15.3%. Nausea is the common complaint — 12% to 18% across the treated groups versus 6% on placebo, with vomiting and diarrhoea behind it — and gastrointestinal effects are the main reason participants stopped treatment.
- Substantial weight loss and appetite control
- Blood-sugar control in type 2 diabetes
- Waist size and visceral fat
- Sleep apnoea severity alongside weight loss
- Liver fat and metabolic-syndrome markers
- Holding weight off over the long run
Common areas of interest, not measured results. The findings below are the published data.
In a 72-week phase 3 double-blind trial in 2,539 adults with obesity and without diabetes, mean body weight fell 15.0%, 19.5% and 20.9% in the 5, 10 and 15 mg tirzepatide groups versus 3.1% with placebo; 57% of the 15 mg group lost at least 20% of body weight versus 3% on placebo.7
In the 176-week extension of that phase 3 obesity trial, among the 1,032 participants who also had prediabetes, type 2 diabetes was diagnosed in 1.3% on tirzepatide versus 13.3% on placebo (hazard ratio 0.07, 95% CI 0.0 to 0.1); mean weight change at 176 weeks was -12.3%, -18.7% and -19.7% in the 5, 10 and 15 mg groups versus -1.3% with placebo.8
In a 72-week open-label phase 3b trial in 751 adults with obesity but without type 2 diabetes, weight fell 20.2% with tirzepatide versus 13.7% with semaglutide at their respective maximum tolerated doses, and waist circumference fell 18.4 cm versus 13.0 cm.9
For laboratory research use only. Not a drug, food, or cosmetic. Not for human or veterinary use, ingestion, or any form of consumption. Sold exclusively to qualified researchers.
